Iterum is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation and IV formulation.

Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Iterum has received Qualified Infectious Disease Product and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.